Home › Funds › Eversept Partners, LP › GSK
Eversept Partners, LP position in GSK
GSK PLC ADR F · Health Care
Eversept Partners, LP reported holding 481,833 shares of GSK (GSK PLC ADR F) in its Q2 2026 13F filing — a position valued at US$25.3M, representing 1.32% of its reported portfolio and ranking #18 among its reported holdings. Eversept Partners, LP has disclosed GSK holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Eversept Partners, LP's GSK position evolved
Eversept Partners, LP first disclosed a stake in GSK in Q3 2023 at 3,259,342 shares (US$118.2M). The position peaked in Q3 2024 at 4,057,206 shares, worth US$165.9M. Across 12 filings, Eversept Partners, LP increased the stake 3 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 481,833 shares valued at US$25.3M — a reduction of -1,303,342 shares quarter over quarter.. Notable position changes include a 28% trim in Q1 2025 (shares were roughly flat over the following quarter), a 33% trim in Q1 2026 (shares fell 5% over the following quarter), a 73% trim in Q2 2026 (shares fell 8% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.26M | $118.15M | New |
| Q4 2023 | 2.97M | $110.18M | Reduce |
| Q1 2024 | 3.77M | $161.71M | Add |
| Q2 2024 | 3.47M | $133.52M | Reduce |
| Q3 2024 | 4.06M | $165.86M | Add |
| Q4 2024 | 3.66M | $123.84M | Reduce |
| Q1 2025 | 2.62M | $101.62M | Reduce |
| Q2 2025 | 2.24M | $86.11M | Reduce |
| Q3 2025 | 2.12M | $91.52M | Reduce |
| Q4 2025 | 2.68M | $131.41M | Add |
| Q1 2026 | 1.79M | $98.52M | Reduce |
| Q2 2026 | 481.83K | $25.26M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GSK and 13F data
GSK (GSK PLC ADR F) is a Health Care company. 23 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.32B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GSK
- Dodge & Cox 48.20M sh · $2.53B · Q2 2026
- DODGE & COX 48.20M sh · $2.53B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 25.18M sh · $1.32B · Q2 2026
- JTC Employer Solutions Trustee Ltd 8.59M sh · $450.31M · Q2 2026
- Mondrian Investment Partners LTD 4.97M sh · $239.21M · Q3 2026
- Grantham, Mayo, Van Otterloo & Co. LLC 3.60M sh · $188.69M · Q2 2026
- EQUITY INVESTMENT CORP 3.27M sh · $171.40M · Q2 2026
More on Eversept Partners, LP
FAQ
How long has Eversept Partners, LP held GSK?
Eversept Partners, LP has disclosed GSK holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Eversept Partners, LP's current position in GSK?
As of Q2 2026, Eversept Partners, LP holds 481.83K shares of GSK (GSK PLC ADR F), valued at $25.26M, representing 1.32% of its reported portfolio and ranking #18.
Has Eversept Partners, LP been buying or selling GSK?
In the latest 13F filing (Q2 2026), Eversept Partners, LP reduced its position in GSK. The position peaked in Q3 2024 at 4.06M shares.
Which other funds hold GSK?
Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 23 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.